Loading...
Price History
Market Data
| Market Cap | 2.44M |
| P/E Ratio | - |
| P/B Ratio | - |
| EPS | -0.25 |
| Dividend Yield | - |
| D/E Ratio | - |
| Current Ratio | 0.24 |
| Currency | USD |
Key Financial Metrics
2.35M
Revenue
-28.03M
Net Income
-0.25
EPS (Diluted)
-51.37M
Free Cash Flow
Profitability
Gross Margin
12.7%
Operating Margin
-1054.9%
Net Profit Margin
-1191.8%
EBITDA
-24.15M
Returns & Efficiency
Return on Assets (ROA)
-584.7%
Return on Equity (ROE)
-
Dividend Yield
-
EPS
-0.25
Financial Health
Total Assets
4.79M
Total Debt
-
Debt to Equity
-
Current Ratio
0.24
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| Industry | Health Services |
| HQ | LONDON |
| Fiscal Year | 2024 |
Peers
NATERA, INC.
NTRA
29.64B
P/E: --
21.16B
P/E: --
21.16B
P/E: --
21.14B
P/E: --
11.88B
P/E: --
11.88B
P/E: --
EXACT SCIENCES CORP
EXAS
9.06B
P/E: --
CELCUITY INC.
CELC
6.80B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap$2.44M
P/E Ratio (TTM)-
Price to Book-
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin12.7%
Operating Margin-1054.9%
Net Margin-1191.8%
ROE-
ROA-584.7%
Leverage & Liquidity
Debt to Equity-
Current Ratio0.24
Total Debt-
Total Assets$4.79M
Stockholders' Equity$-11.32M
Income Statement (FY 2024)
Revenue$2.35M
Gross Profit$299.00K
Operating Income$-24.81M
Net Income$-28.03M
EPS (Diluted)$-0.25
Cash Flow (FY 2024)
Free Cash Flow$-51.37M
Cash & Equivalents$909.00K
Revenue Growth2.8%
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | FINSGATE 5-7 CRANWOOD STREET LONDON, None EC1V 9EE |
| Phone | 44 29 2071 0570 |
| Incorporated | DE, US |
| EIN | 000000000 |
| Fiscal Year End | 0630 |
| Shares Outstanding | 105.70M |
| Stockholders' Equity | $-11.32M |
| Cash & Equivalents | $909.00K |
Recent Filings
View All
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2024-11-25
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2024-10-11
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2024-09-30
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2024-03-29
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2023-11-13
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | RENALYTIX PLC |
| Ticker | RENXF |
| Exchange | -- |
| Sector | Services |
| Industry | Health Services |
| Headquarters | LONDON |
| Fiscal Year | 2024 |
Financial Summary
| Market Cap | 2.44M |
| Revenue | 2.35M |
| Net Income | -28.03M |
| P/E Ratio | - |
| EPS | -0.25 |
| Net Margin | -1191.8% |
| ROE | - |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...